Transplant Oncology - The Evolving Frontier in Liver Transplantation

17K
views
77
authors
7
articles
Editors
3
Impact
Loading...
3,590 views
6 citations
Review
21 November 2022

Intrahepatic cholangiocarcinoma (iCCA) is a primary epithelial cell malignancy of the liver with rising incidence rate globally. Its insidious presentation, heterogeneous and aggressive biology, and recalcitrance to current therapies results in unacceptably high morbidity and mortality. This has spurred research efforts in the last decade to better characterize it molecularly with translation to improved diagnostic tools and treatments. Much of this has been driven by patient advocacy. This has renewed interest in orthotopic liver transplantation (LT) with adjunctive therapies for iCCA, which was historically disparaged due to poor recipient outcomes and donor organ scarcity. However, the optimal use of LT as a treatment for iCCA care remains unclear. Here, we review the epidemiology of iCCA, the history of LT as a treatment modality, alternative approaches to iCCA local control, the evidence for peri-operative systemic therapies, and the potential roles of biomarkers and targeted agents. In doing so, we hope to prioritize areas for continued research and identify areas where multidisciplinary care can improve outcomes.

3,137 views
15 citations

Background: Liver transplantation (LT) is considered a therapeutic option for unresectable perihilar cholangiocarcinoma (PHC) within defined criteria. It remains uncertain whether patients can safely receive adjuvant chemotherapy after LT.

Methods: We performed a prospective, multi-center, randomized, non-blinded two-arm trial (pro-duct001). Patients after LT for unresectable PHC within defined criteria were randomized to adjuvant gemcitabine (LT-Gem group) and LT alone (LT alone group). The primary objective was to investigate if adjuvant chemotherapy is feasible in ≥ 85% of patients after LT. The primary endpoint was the percentage of patients completing the 24 weeks course of adjuvant chemotherapy. Secondary endpoints included overall survival (OS) and disease-free (DFS), and complication rates.

Results: Twelve patients underwent LT for PHC, of which six (50%) were eligible for randomization (LT-Gem: three patients, LT alone: three patients). Two out of three patients discontinued adjuvant chemotherapy after LT due to intolerance. The study was prematurely terminated due to slow enrollment. One patient with PHC had underlying primary sclerosing cholangitis (PSC). Tumor-free margins could be achieved in all patients. In both the LT-Gem and the LT alone group, the cumulative 1-, 3-, and 5-year OS and DFS rates were 100%, 100%, 67%, and 100%, 67% and 67%, respectively.

Conclusions: This prospective, multi-center study was prematurely terminated due to slow enrollment and a statement on the defined endpoints cannot be made. Nevertheless, long-term survival data are consistent with available retrospective data and confirm defined criteria for LT. Since more evidence of LT per se in unresectable PHC is urgently needed, a prospective, non-randomized follow-up study (pro-duct002) has since been launched.

2,557 views
8 citations
Open for submission
Frontiers Logo

Frontiers in Pharmacology

Nanopharmacology for Neurology and Oncology
Edited by Vinay Bhardwaj, Ajeet Kaushik, Ziad Khatib, Anthony McGoron, Madhavan N Nair
31.7K
views
40
authors
6
articles
Recommended Research Topics
Frontiers Logo

Frontiers in Pharmacology

Nanopharmacology for Neurology and Oncology
Edited by Vinay Bhardwaj, Ajeet Kaushik, Ziad Khatib, Anthony McGoron, Madhavan N Nair
31.7K
views
40
authors
6
articles
Frontiers Logo

Frontiers in Aging Neuroscience

Progress in Pharmacological Approaches and Drug Delivery Strategies Targeting Neurological Ailments
Edited by George Barreto, Andreas Martin Grabrucker, Rubem C.A. Guedes
184.2K
views
87
authors
15
articles
Frontiers Logo

Frontiers in Pharmacology

Classical and Modern Biotechnology Applied to the Treatment of Epilepsy and Anxiety Disorders
Edited by Renê Oliveira Beleboni, Norberto Cysne Coimbra, Márcia Renata Mortari, Liana Melo-Thomas
37.4K
views
27
authors
5
articles
Frontiers Logo

Frontiers in Neuroscience

Emerging Inner Ear Therapies
Edited by Andrei N Lukashkin, Nils Kristian Prenzler, Ian Russell, Monica A Serban, Tal Teitz, Peter S Steyger, Timur I. Abdullin, Athanasia Warnecke
26.9K
views
21
authors
5
articles
Frontiers Logo

Frontiers in Pharmacology

Identifying Novel Drug Delivery Systems and Treatments for Hearing Loss and Related Ear Disorders, Volume II
Edited by Sho Kanzaki, Taro Yamaguchi, Myung-Whan Suh
18.8K
views
39
authors
7
articles